2023
Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19
Scheim D, Vottero P, Santin A, Hirsh A. Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19. International Journal Of Molecular Sciences 2023, 24: 17039. PMID: 38069362, PMCID: PMC10871123, DOI: 10.3390/ijms242317039.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 spike proteinRed blood cellsCOVID-19Severe COVID-19 patientsSpike proteinSevere COVID-19COVID-19 correlatesCOVID-19 patientsCommon cold infectionsCOVID-19 morbidityLong-COVID patientsFuture therapeutic strategiesSARS-CoV-2Key risk factorsKey morbiditiesSurface of plateletsSevere morbidityClinical efficacyVascular damageViral loadMicrovascular occlusionRisk factorsCOVID patientsClinical studiesClinical susceptibilityComputational Prediction of the Interaction of Ivermectin with Fibrinogen
Vottero P, Tavernini S, Santin A, Scheim D, Tuszynski J, Aminpour M. Computational Prediction of the Interaction of Ivermectin with Fibrinogen. International Journal Of Molecular Sciences 2023, 24: 11449. PMID: 37511206, PMCID: PMC10380762, DOI: 10.3390/ijms241411449.Peer-Reviewed Original ResearchConceptsSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Acute COVID-19Coagulation factor fibrinogenSyndrome coronavirus 2Interactions of ivermectinBlood coagulation factor fibrinogenSARS-CoV-2 spike proteinAbnormal blood clotsAntiparasitic drug ivermectinLong COVIDFactors fibrinogenCoronavirus 2Proinflammatory activityClot propertiesPathologic thrombosisClot formationBlood clotsDrug ivermectinIvermectinFibrinogen peptidesFibrin clotsCOVID-19
2021
Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma
Levi G, Rocchetti C, Magri R, Uccelli S, Bottone D, Quadri F, Novali M, Santin AD, Bezzi M. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. Monaldi Archives For Chest Disease 2021, 91 PMID: 34121379, DOI: 10.4081/monaldi.2021.1867.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19FemaleHumansImmunocompromised HostLymphoma, FollicularMiddle AgedSARS-CoV-2Treatment OutcomeConceptsPlasma infusionFollicular lymphomaHyperimmune plasmaCOVID-19COVID-19 patientsStandard of careInflammatory indexFirst doseImmunocompetent patientsRadiological findingsSecond doseNasopharyngeal swabsPoor prognosisCaucasian womenImproved outcomesPositive testPatientsSubsequent onsetLimited dataFeverLymphomaInfusionDoseDaysObinutuzumab